<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8399">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126904</url>
  </required_header>
  <id_info>
    <org_study_id>1310006</org_study_id>
    <nct_id>NCT02126904</nct_id>
  </id_info>
  <brief_title>Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept</brief_title>
  <official_title>Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators compared the time to recurrence after ranibizumab or aflibercept loading
      in patients with AMD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Time to recurrence after induction phase</measure>
    <time_frame>More than 3 months from baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time frame depends on patients because recurrence time is different.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>The Injection Burden</condition>
  <arm_group>
    <arm_group_label>IVR group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA group</intervention_name>
    <arm_group_label>IVR group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients were treated at Yokohama City University Medical Center between January
        2012 and October 2013.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They must have had BCVA better than 20/400 and had three consecutive induction
             treatment of ranibizumab or aflibercept.

        Exclusion Criteria:

          -  patients with eye diseases that could potentially influence the visual acuity of the
             studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous
             retinal detachment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maiko Inoue, M.D.</last_name>
      <phone>81 45 261 5656</phone>
      <phone_ext>7458</phone_ext>
      <email>maicoo@urahp.yokohama-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Maiko Inoue, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yokohama City University Medical Center</investigator_affiliation>
    <investigator_full_name>Maiko Inoue</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
